Performance and safety of the second-generation female condom (FC2) versus the Woman's, the VA worn-of-women, and the Cupid female condoms: a randomised controlled non-inferiority crossover trial  Dr Mags E Beksinska, PhD, Gilda Piaggio, PhD, Jennifer A Smit, PhD, Junqing Wu, PhD, Yufeng Zhang, MSc, Jacqueline Pienaar, MSc, Ross Greener, MSocSc, Ying Zhou, MSc, Carol Joanis, BSc  The Lancet Global Health  Volume 1, Issue 3, Pages e146-e152 (September 2013) DOI: 10.1016/S2214-109X(13)70054-8 Copyright © 2013 Beksinska et al. Open Access article distributed under the terms CC BY-NC-ND Terms and Conditions

Figure 1 Trial profile The numbers of women withdrawing after period one were two for the sequence CWVF, three for FVWC, none for VCFW, and three for WFCV; after period two were three, two, one, and two, respectively; and for period three were three, two, one, and two, respectively. C=Cupid. W=Woman's Condom. V=VA worn-of-women. F=second-generation female condom (FC2). The Lancet Global Health 2013 1, e146-e152DOI: (10.1016/S2214-109X(13)70054-8) Copyright © 2013 Beksinska et al. Open Access article distributed under the terms CC BY-NC-ND Terms and Conditions

Figure 2 Description of study products The Lancet Global Health 2013 1, e146-e152DOI: (10.1016/S2214-109X(13)70054-8) Copyright © 2013 Beksinska et al. Open Access article distributed under the terms CC BY-NC-ND Terms and Conditions

Figure 3 Estimates of the risk difference between failure of new female condoms and failure of FC2, for the primary outcomes of TFCF and TCF, showing the results for non-inferiority TFCF=total female condom failure. VA wow=VA worn-of-women. TCF=total clinical failure. FC2=second-generation female condom. The Lancet Global Health 2013 1, e146-e152DOI: (10.1016/S2214-109X(13)70054-8) Copyright © 2013 Beksinska et al. Open Access article distributed under the terms CC BY-NC-ND Terms and Conditions